Paper Title
UNVEILING THE BIOTECHNOLOGICAL POTENTIAL OF BLACK FUNGUS

Abstract
Mucormycosis, commonly referred to as "black fungus," emerged as a severe opportunistic infection during the COVID-19 pandemic, particularly affecting immunocompromised individuals. This aggressive fungal disease, caused by members of the order Mucorales, is associated with high morbidity and mortality due to its rapid progression and limited therapeutic options. Traditional antifungal treatments such as amphotericin B, although effective, are constrained by toxicity, cost, and the risk of resistance development. Recent advancements in biotechnology present novel opportunities for the prevention and management of mucormycosis. Biotechnological approaches such as molecular diagnostics enable early and accurate detection of fungal pathogens, reducing diagnostic delays. Genetic engineering and synthetic biology hold promise in developing antifungal peptides, immunomodulatory therapies, and engineered probiotics that may enhance host defense mechanisms. Additionally, nanotechnology-based drug delivery systems are being explored to improve the efficacy and reduce the toxicity of antifungal drugs.Preventive strategies can further be strengthened through the integration of biotechnology in public health surveillance, rapid point-of-care diagnostic tools, and biomarker-based risk assessment in vulnerable populations. Furthermore, biotechnology-driven innovations in vaccine development against mucormycosis represent a transformative step towards long-term prevention. This study explores the diverse biotechnological interventions that can play a pivotal role in combating mucormycosis and mitigating its impact on human health. By highlighting the potential of biotechnology in early detection, treatment, and prevention, this work emphasizes the need for interdisciplinary research to address emerging fungal threats. Keywords - Mucormycosis, Black Fungus, Biotechnology, Prevention, Nanotechnology, Antifungal Therapy